Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future

被引:3
作者
Wang Lun [1 ,2 ,3 ,4 ,5 ]
Zhang Yang [1 ,2 ,3 ,4 ,5 ]
Zhang ShuYang
机构
[1] Department of Cardiology
[2] Peking Union Medical College Hospital
[3] Peking Union Medical College & Chinese Academy of Medical Sciences
[4] Beijing
[5] China
关键词
Cardiovascular disease; Coronary artery disease; Rheumatoid arthritis;
D O I
暂无
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objective: To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis (RA)-associated coronary artery disease (CAD), and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen.Data sources: This study was based on data obtained from PubMed up to May 2019 using various search terms and their combinations, including coronary artery disease, myocardial ischemia, cardiovascular diseases, RA, rheumatic diseases, treatment, therapy, strategies, immunotherapy, inflammation, and anti-inflammation.Study selection: All retrieved literature was scrutinized, most relevant articles about the pathogenic mechanism and clinical management, especially anti-inflammatory therapy of RA-associated CAD were reviewed.Results: RA is an immune-mediated chronic inflammatory disease which has a great social disease burden. In addition to typical arthritic manifestations, RA also affects extra-articular tissues and organs, within which the involvement of the cardiovascular system, especially incorporating CAD, is the leading cause of death for patients with RA. Recently, numerous basic and clinical studies have been carried out on the mechanism of CAD development and progression under the inflammatory cascade of RA. The effect of traditional RA drugs on CAD risk management has been gradually clarified, and more emerging biologic agents are being explored and studied, which have also achieved satisfactory outcomes. Furthermore, with the success of the CANTOS clinical trial, novel anti-inflammatory therapy for the prevention of cardiovascular disease is believed to have a broad prospect.Conclusions: RA is an independent risk factor for CAD, which mainly results from the underlying inflammatory cascade; therefore, anti-inflammatory therapy, especially the emerging novel biologic drugs, is important for CAD management in patients with RA and may also be a promising approach among the general population.
引用
收藏
页码:2972 / 2983
页数:12
相关论文
共 91 条
[1]  
Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function[J] . Ikonomidis Ignatios,Pavlidis George,Katsimbri Pelagia,Andreadou Ioanna,Triantafyllidi Helen,Tsoumani Maria,Varoudi Maria,Vlastos Dimitrios,Makavos George,Kostelli Gavriella,Βenas Dimitrios,Lekakis John,Parissis John,Boumpas Dimitrios,Alexopoulos Dimitrios,Iliodromitis Efstathios.Clinical research in cardiology : official journal of the German Cardiac Society . 2019 (10)
[2]  
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study[J] . Gottenberg Jacques-Eric,Morel Jacques,Perrodeau Elodie,Bardin Thomas,Combe Bernard,Dougados Maxime,Flipo Rene-Marc,Saraux Alain,Schaeverbeke Thierry,Sibilia Jean,Soubrier Martin,Vittecoq Olivier,Baron Gabriel,Constantin Arnaud,Ravaud Philippe,Mariette Xavier.BMJ (Clinical research ed.) . 2019
[3]  
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions[J] . Paolo Raggi,Jacques Genest,Jon T. Giles,Katey J. Rayner,Girish Dwivedi,Robert S. Beanlands,Milan Gupta.Atherosclerosis . 2018
[4]   Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation [J].
Zeisbrich, Markus ;
Yanes, Rolando E. ;
Zhang, Hui ;
Watanabe, Ryu ;
Li, Yinyin ;
Brosig, Lukas ;
Hong, Jison ;
Wallis, Barbara B. ;
Giacomini, John C. ;
Assimes, Themistocles L. ;
Goronzy, Jorg J. ;
Weyand, Cornelia M. .
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (07) :1053-1062
[5]  
Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities[J] . Jay Khambhati,Marc Engels,Marc Allard-Ratick,Pratik B. Sandesara,Arshed A. Quyyumi,Laurence Sperling.Atherosclerosis . 2018
[6]  
Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction[J] . Ola Kleveland,Thor Ueland,Gabor Kunszt,Marte Bratlie,Arne Yndestad,Kaspar Broch,Espen Holte,Liv Ryan,Brage H. Amundsen,Bj?rn Bendz,Svend Aakhus,Terje Espevik,Bente Halvorsen,Tom E. Mollnes,Rune Wiseth,Lars Gullestad,P?l Aukrust,Jan Kristian Dam?s.International Journal of Cardiology . 2018
[7]  
Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population‐based cohort study[J] . Yao‐Min Hung,Yu‐Hsun Wang,Lichi Lin,Paul Yung Pou Wang,Jeng‐Yuan Chiou,James Cheng‐Chung Wei.International Journal of Clinical Practice . 2018 (5)
[8]  
Malondialdehyde–acetaldehyde antibody concentrations in rheumatoid arthritis and other rheumatic conditions[J] . Ted R. Mikuls,Michael J. Duryee,Bryant R. England,Daniel R. Anderson,Michelene Hearth-Holmes,Kaihong Su,Kaleb Michaud,Jeffrey B. Payne,Harlan Sayles,Carlos Hunter,Jacob D. McGowan,Lynell W. Klassen,Geoffrey M. Thiele.International Immunopharmacology . 2018
[9]  
Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis[J] . Claire Rempenault,Bernard Combe,Thomas Barnetche,Ce?cile Gaujoux-Viala,Ce?e?dric Lukas,Jacques Morel,Charlotte Hua.Annals of the Rheumatic Diseases . 2018 (1)
[10]   Adipose tissue complement factor B promotes adipocyte maturation [J].
Matsunaga, Hiroaki ;
Iwashita, Misaki ;
Shinjo, Takanori ;
Yamashita, Akiko ;
Tsuruta, Mitsudai ;
Nagasaka, Shoichiro ;
Taniguchi, Ataru ;
Fukushima, Mitsuo ;
Watanabe, Naoya ;
Nishimura, Fusanori .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 495 (01) :740-748